Internal Medicine Journal

Cover image for Vol. 45 Issue 10

Edited By: Jeff Szer

Impact Factor: 1.644

ISI Journal Citation Reports © Ranking: 2014: 62/153 (Medicine General & Internal)

Online ISSN: 1445-5994

Recently Published Issues

See all

Top 5 Cited Papers - 2013 Impact Factor Period

Variability in vitamin D assays impairs clinical assessment of vitamin D status
J. K. C. Lai, R. M. Lucas, E. Banks, A.-L. Ponsonby and the Ausimmune Investigator Group

Diabetes as a risk factor for dementia and mild cognitive impairment: a meta-analysis of longitudinal studies
G. Cheng, C. Huang, H. Deng and H. Wang

Clinical heterogeneity and prognostic features of South Australian patients with anti-synthetase autoantibodies
M. Dugar, S. Cox, V. Limaye, P. Blumbergs and P. J. Roberts-Thomson

Use of empiric antimicrobial therapy in neutropenic fever
C. S. Tam, M. O'Reilly, D. Andresen, S. Lingaratnam, A. Kelly, K. Burbury, J. Turnidge, M. A. Slavin, L. J. Worth, L. Dawson and K. A. Thursky

New onset sarcoid-like granulomatosis developing during anti-TNF therapy: an under-recognised complication
D. Tong, N. Manolios, G. Howe and D. Spencer

Editor's Choice

Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort

A. Mallett, P. Hughes, J. Szer, A. Tuckfield, C. Van Eps, S. B. Cambell, C. Hawley, J. Burke, J. Kausman, I. Hewitt, A. Parnham, S. Ford and N. Isbel

This study aimed to report the clinical characteristics and outcomes of Australian patients treated with eculizumab for atypical haemolytic uraemic syndrome (aHUS). A retrospective cohort study was undertaken of all patients in Australia treated with eculizumab provided in a compassionate access programme for a clinical diagnosis of aHUS using prospectively collected clinical data.